News

The Pentagon just earmarked over $74 billion for drone dominance and counter drone technologies in the FY2027 budget request, and that is only one slice of the AI arms race AMD and NVIDIA are fighting over. While Wall Street obsesses over who wins the GPU throne, the real money in the next AI phase is ... AMD Is Up 150% This Year But Here Are 5 Overlooked Stocks Betting on What Comes Next

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Schrödinger, Inc. (NASDAQ:SDGR) is among the Best Pharmaceutical Stocks. On May 14, Morgan Stanley lowered its price target on Schrödinger, Inc. (NASDAQ:SDGR) to $17 from $19. The firm maintained an “Equal Weight” rating on the shares. Separately, Schrödinger, Inc. (NASDAQ:SDGR) maintained full-year guidance for ACV of $218 million to $228 million. The corporation expects 10% to […]

Schrodinger Inc (NASDAQ:SDGR) is one of the best long-term stocks to invest in according to Bill & Melinda Gates Foundation Trust. The stock is backed by 31 hedge funds. Schrodinger shares are up around 13% over the past month, and analysts see more upside in the stock. On June 9, Schrodinger Inc (NASDAQ:SDGR) announced it […]

Schrödinger’s fair value estimate has been trimmed slightly from US$21.38 to US$20.88, bringing it in line with the updated implied price target in the model. This mirrors recent Street research, where several firms have also cut price targets while stressing that the shift reflects refreshed views on valuation, revenue recognition and execution risks rather than a single catalyst. As you read on, you will see how these moving targets shape the evolving analyst narrative and what to watch...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside Potential

It's been a pretty great week for Schrödinger, Inc. ( NASDAQ:SDGR ) shareholders, with its shares surging 11% to...

Schrödinger (SDGR) is back in focus after first quarter earnings. Revenue held near prior year levels, and sales, net loss and per share figures gave investors fresh data on the company’s current spending profile. See our latest analysis for Schrödinger. The stock has seen an 11.14% 1 month share price return and a 5.15% 7 day share price return. However, the year to date share price return shows a 28.42% decline and the 1 year total shareholder return reflects a 45.37% loss, indicating that...

Moby summary of Schrödinger, Inc.'s Q1 2026 earnings call

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti

​Schrödinger, Inc. (NASDAQ:SDGR) is a scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science. While the stock is trading close to its all-time low, analysts expect more than 69% upside over the next 12-months from the current level. The stock ranks eighth on our of […]

Schrodinger Inc (NASDAQ:SDGR) is among the best medical AI stocks to buy now. Schrodinger Inc (NASDAQ:SDGR)’s management presented at the 2026 KeyBanc Capital Markets Healthcare Forum on March 17. The presentation covered the company’s strategic direction, with the management discussing a shift to hosted software contracts and leveraging AI to expand the user base. The […]

Schrödinger’s fair value estimate has been trimmed from US$23.50 to US$21.38, a move that lines up with a wider round of price target cuts across the Street. Analysts tying these changes to the growing mix of hosted software point to short term noise in reported revenue and investor perception, even as some maintain Buy ratings and focus on underlying usage trends. As you read on, you will see how to track these shifting targets and what they may signal for the evolving Schrödinger...

Schrodinger (NASDAQ:SDGR) executives outlined a strategy focused on expanding adoption of its computational chemistry platform, accelerating a shift to hosted software delivery, and partnering out internal clinical-stage assets during a virtual fireside chat at an annual healthcare forum. Platform